Eli Lilly issued a public warning regarding safety risks in compounded versions of tirzepatide. This active ingredient is used in the company’s Zepbound and Mounjaro treatments.
Internal testing of unregulated products revealed significant impurities. These risks increase when pharmacies mix tirzepatide with vitamin B12.
Lilly claims some compounding pharmacies use additives with no proven clinical benefit. The company urged the FDA to recall compounded products containing these untested substances.
The warning addresses the rising market for cheaper, copycat versions of obesity and diabetes drugs. Eli Lilly and its competitors continue to face pressure from these unregulated alternatives.